Table 2.

Patient Selection for Use of Liquid Suspension of Spironolactone in Patients with Heart Failure

Patients	Class of Recommendation/LOE	Dose	Comments
● Patients with HFrEF, NYHA class II-IV	I/A	Initial dose: 12.5–25 mg qd; maximal dose 25 mg qd – 25 mg bid
● Patients with HFpEF	IIb/B	Same	Additional selection criteria: LVEF ≥45%, elevated BNP levels or HF admission within 1 year, eGFR >30 mL/min, creatinine <2.5 mg/dL, potassium <5.0 mEq/L
● Candidate patients with difficulty in swallowing or unable to swallow tablet drug forms		Same
● Candidate patient preference/acceptability		Same	Ease of swallowing, drug flavor/taste

Abbreviations: BNP, brain natriuretic peptide; eGFR, estimated glomerular filtration rate; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; LOE, level of evidence; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.